The exocytosis of insulin from pancreatic b -cells is closely related to intracellular elevation of Ca 2+ . The effects of Ca 2+ may be mediated by Ca 2+ / calmodulin-dependent protein kinase II (CaMKII). Four subunits of CaMKII, termed a , b , g, and d , are encoded by distinct genes, and various isoforms of these subunits exist as different splicing variants. In the brain, phosphorylation of synapsin I by the a isoform induces neurotransmitter release. In order to clarify whether phosphorylation of synapsin I by CaMKII was involved in insulin exocytosis, we cloned the isoforms of CaMKII and synapsin I from mouse insulinoma MIN6 cells. We found that b'e and d 2 are the major isoforms of CaMKII and that synapsin Ib is a major isoform of synapsin I in MIN6 cells. It was interesting that d 2 and synapsin Ib were co-localized with insulin secretory granules in the cells. Treatment of MIN6 cells with glucose and tolbutamide rapidly activated CaMKII. Immunoblot analysis with two antibodies against synapsin I phosphorylated by CaMKII demonstrated the increase in phosphorylation of synapsin I by the secretagogues. Furthermore, the secretagogue-induced phosphorylation of synapsin I and insulin secretion were potentiated by transient overexpression of the b'e or d 2 isoform. These results suggest that activation of CaMKII and the concomitant phosphorylation of synapsin I induce insulin exocytosis from pancreatic b-cells.
Introduction
Intracellular Ca 2+ has been reported to play a critical role in secretagogue-induced insulin exocytosis (1) . Stimulation of pancreatic b-cells with secretagogues such as glucose and tolbutamide results in a rise in intracellular Ca 2+ concentration mainly due to Ca 2+ influx from the extracellular space (2) . Many effects of Ca 2+ on the various cellular functions are mediated through calmodulin (CaM), and the effects of Ca 2+ / CaM may be mediated by Ca 2+ / CaM-dependent protein kinase II (CaMKII) (3, 4) . It has been reported that W-7, a CaM inhibitor, inhibits the movement of insulin secretory granules and insulin secretion from b-cells (5) .
Furthermore, CaMKII inhibitors such as KN-62 and KN-93 inhibit insulin secretion from insulinoma cells and rat pancreatic islets (6, 7) .
CaMKII contains four subunits, a , b, g, and d , encoded by distinct genes in eukaryotes (8, 9) . Various isoforms of these subunits exist as different splicing variants. Certain isoforms of CaMKII have been identified in pancreatic islets (6, 10 -12) and insulinoma cell lines (13, 14) . CaMKII phosphorylates proteins that are thought to be involved in the traffic, docking, and fusion of insulin secretory granules. These include synapsin I (13, 15) , microtubule-associated protein 2 (MAP2) (16) , N-ethylmaleimide-sensitive fusion protein (NSF), soluble NSF attachment protein (SNAP), vesicleassociated membrane protein (VAMP / synaptobrevin) (17), a -SNAP (18), SNAP-25, and synaptotagmin (19) . Among the substrates for CaMKII, synapsin I is one of the most attractive candidates for the regulation of insulin secretion. In the brain, the a isoform plays a critical role in the regulation of the neurotransmitter release via phosphorylation of synapsin I (20) . We found that treatment of MIN6 cells, one of the insulinoma cell lines, with secretagogues such as glucose, tolbutamide, and high K + induced activation of CaMKII and phosphorylation of synapsin I-like protein with a concomitant rise in insulin secretion (13) . Similar findings were reported using isolated rat pancreatic islets (21) . We found that synapsin I was abundant in MIN6 cells and the cloning of synapsin I in the cells revealed that the major isoform was synapsin Ib (22) .
In the present study, we identified the isoforms of CaMKII in MIN6 cells and found that b'e and d 2 are major isoforms in the cells. Biochemical studies revealed that d 2 was associated with synapsin Ib at insulin secretory granules. Furthermore, we investigated the effects of overexpression of the major isoforms on phosphorylation of synapsin I and insulin secretion (23) .
Identification of mRNAs of CaMKII isoforms in MIN6 cells and rat islets
By Northern blot analysis, the mRNAs of b and d subunits were readily detected, whereas those of a and g subunits were less evident in MIN6 cells. When we investigated the subunits of CaMKII in rat islets, we could not detect any subunits by Northern blot analysis. In the next step, we tried to isolate all isoforms of CaMKII by RT-PCR from MIN6 cells and rat islets. Sequencing of the PCR products showed that the obtained cDNAs from MIN6 cells were a , a B, b'e, gB, gC, d 2, and d 6, whereas only b 'e was obtained from rat islets.
Immunoblot analysis of CaMKII isoforms in MIN6 cells and rat islets
Using an antibody to CaMKII, we found that the apparent molecular mass of the major subunit in MIN6 cells was 55 kDa (13) . When we overexpressed b'e and d 2, both isoforms comigrated at the same position as the 55-kDa protein. Furthermore, the antibody to the b or d subunit detected the 55-kDa protein in MIN6 cells, whereas only the antibody to the b subunit detected the 55-kDa protein in rat islets. These results strongly suggested that the identified isoforms of CaMKII in MIN6 cells and rat islets were b'e and d 2, and b 'e, respectively, at the protein level.
Co-localization of synapsin Ib and d 2 with secretory granules in MIN6 cells
In neuronal cells, synapsin I and the a isoform of CaMKII were reported to be associated with synaptic vesicles (20) . Therefore, we considered the possibility that synapsin Ib and CaMKII in MIN6 cells are associated with insulin secretory granules. We carried out sucrose gradient subcellular fractionation using the MIN6 cell extracts. Immunoblot analysis and measurement of immunoreactive insulin with individual fractions clearly indicated that synapsin Ib and d 2 were cofractionated with insulin secretory granules in MIN6 cells ( Fig. 1 ).
Activation of the b'e and d 2 overexpressed in MIN6 cells
In order to examine the involvement of b'e and d 2 isoforms in secretagogue-induced insulin secretion, the isoforms were overexpressed in MIN6 cells. Immunostaining of the transfected cells indicated that the transfection efficiency of MIN6 cells was about 36%. The activity of CaMKII in the extract from the cells transfected with the b 'e or d 2 isoform was about 2.5-fold higher than that of mock-transfected cells and was dependent on Ca 2+ / calmodulin.
In the next step, we examined whether or not over- expressed isoforms were activated in a manner similar to that of endogenous CaMKII. Autophosphorylation of overexpressed b'e and d 2 was higher than that in mock-transfected cells and increased by treatment with 0.37 mM tolbutamide within 3 min. Furthermore, we examined the generation of the Ca 2+ / CaM-independent form of CaMKII by tolbutamide treatment. Treatment of the cells with 0.37 mM tolbutamide for 3 min increased Ca 2+ /CaM-independent activity to 1.39 ± 0.01-, 1.43 ± 0.06-, and 1.45 ± 0.02-fold in mock-, b'e-, and d 2-transfected cells, respectively (n = 6). These results indicate that the overexpressed isoforms are activated by tolbutamide through autophosphorylation and generation of Ca 2+ / CaM-independent forms.
Potentiation of phosphorylation of synapsin I by overexpression of b 'e and d 2
We next examined whether overexpression of b'e and d 2 increased phosphorylation of synapsin I. As we found that synapsin Ib was a major isoform of synapsin I in MIN6 cells, we used the antibodies specific to synapsin Ib phosphorylated at serine 566 (Ser-566) (termed pS566-Syn I-Ab) and Ser-603 (termed pS603-Syn I-Ab), which are recognized as phosphorylation sites by CaMKII. Treatment of MIN6 cells with 25 mM glucose increased phosphorylation of synapsin Ib at Ser-566 and Ser-603 with a peak occurring after 5-min incubation, and it gradually decreased to the basal level in 15 min. Treatment of MIN6 cells with tolbutamide induced a rapid increase in the phosphorylation with the peak level noted after 3 min, which also decreased to the basal level within 15 min.
Without any secretagogues, overexpression of b'e or d 2 did not increase phosphorylation of synapsin I compared to mock-transfected cells. However, overexpression of each isoform potentiated the increase in the phosphorylation by glucose and tolbutamide treatments. When phosphorylation of Ser-566 after 5-min treatment of mock-transfected cells with glucose was taken as 100%, overexpression of b'e and d 2 potentiated the phosphorylation to 651.8 ± 34.3% and 371.6 ± 11.1%, respectively. Phosphorylation of Ser-603 by glucose and tolbutamide treatments was also potentiated by overexpression of the isoforms.
Potentiation of insulin secretion by overexpression of b 'e and d 2
In the next series of experiments, we examined whether overexpression of b'e and d 2 increased insulin secretion. Without any secretagogues, overexpression of b'e or d 2 did not increase insulin secretion compared to mock-transfected cells. Treatment of mock-transfected cells with glucose and tolbutamide for 10 min significantly increased insulin secretion from 141.4 ± 8.0 U/ mg to 169.8 ± 3.0 U / mg and 178.4 ± 4.3 U/ mg, respectively. Overexpression of b'e and d 2 potentiated glucose-induced insulin secretion to 192.6 ± 9.4 and 190.7 ± 8.3 U/ mg, respectively. Tolbutamide-induced insulin secretion was also potentiated by overexpression of b'e and d 2 to 225.4 ± 7.8 and 241.5 ± 17.0 U/ mg, respectively.
Overexpression of b'e(K43A) and d 2(K43A) mutants and their effects on insulin secretion
To confirm that the activity of CaMKII was necessary for potentiation of insulin secretion, we generated b'e(K43A) and d 2(K43A) mutants by site-directed mutagenesis. Immunoblot analysis revealed that expression levels of both mutants and wild types of b'e and d2 were comparable to one another. We confirmed that the activity of CaMKII in the extract was not increased by overexpression of either mutant. Furthermore, overexpression of either mutant did not increase insulin secretion in the presence or absence of tolbutamide compared to mock-transfected cells.
Discussion
It has been reported that some isoforms of CaMKII are targeted to specific cellular compartments. The a isoform is associated both with postsynaptic densities (9) and synaptic vesicles (20) . The a B and d 3 isoforms are targeted to the nucleus (24, 25) and the d 2 isoform in astrocytes is localized predominantly at the Golgi apparatus (26) . Therefore, identification of the isoforms in MIN6 cells is important to deduce the subcellular localization and physiological functions in the cells. We found that the b'e and d 2 were the major isoforms in MIN6 cells, and only b'e was detected in rat islets. The b'e isoform was originally found in rat brains (24) , and, to our knowledge, our finding is apparently the first report on the occurrence of b'e in insulinoma cells and rat islets. The b3 isoform has been reported to be present in MIN6 cells as well as neonatal rat islets and human islets at the mRNA level (11, 12) . However, we could not detect the b 3 isoform under our experimental conditions. At the present, it is not clear why there are differences between the experimental results.
In the brain, the binding of synapsin I to synaptic vesicles is regulated by the a isoform which also binds to synaptic vesicles. Phosphorylation of synapsin I by the a isoform decreases the affinity of binding of synapsin I to synaptic vesicles and mobilizes them for neurotransmitter release (Fig. 2) . We found that synapsin Ib and the d 2 isoform bind to insulin secretory granules, and our results strongly suggested that phosphorylation of synapsin I by CaMKII is involved in insulin exocytosis by glucose and tolbutamide treatments (Fig. 2) . It should be noted that glucose and tolbutamide induce insulin exocytosis due to Ca 2+ influx from the extracellular space by membrane depolarization. Therefore, phosphorylation of synapsin I by CaMKII may be crucial for both neurotransmitter release and insulin exocytosis induced by membrane depolarization. It may be interesting to examine whether or not phosphorylation of synapsin I by CaMKII is also involed in insulin exocytosis induced by Ca 2+ release from intracellular storage sites.
We noticed that overexpression of CaMKII was not sufficient for insulin exocytosis. Therefore, some molecular mechanisms other than activation of CaMKII may be needed to induce the exocytosis. The SNARE complex and synaptotagmin have important roles in neurotransmitter release (27) . Synaptotagmin is an integral Ca 2+ -binding protein of synaptic vesicle membranes and binding of Ca 2+ to synaptotagmin is necessary for the fusion of the membranes of synaptic vesicles and the presynaptic terminal. As synaptotagmin was reported to exist in MIN6 cells and pancreatic b-cells (28), the similar mechanisms may be involved in insulin exocytosis. An elevation of Ca 2+ beneath the plasma membrane by secretagogues may be necessary for fusion of insulin secretory granules to the plasma membrane. Fig. 2 . Involvement of phosphorylation of synapsin I by CaMKII in neurotransmitter release and insulin exocytosis. A: An action potential in the axon is conveyed to the nerve terminal and induces membrane depolarization. The opening of L-type voltage-dependent Ca 2+ channels (VDCC) increases intracellular Ca 2+ concentration, followed by activation of a isoform. B: Oxidative metabolism of glucose (TCA cycle) induces a rise in the cytosolic ATP /ADP, which closes K-ATP channels, followed by membrane depolarization. Tolbutamide directly closes K-ATP channels. The opening of VDCC increases intracellular Ca 2+ concentration, followed by activation of b 'e and d2 isoform. Phosphorylation of synapsin I by CaMKII induces the translocation of synaptic vesicles (A) or insulin secretory granules (B) beneath the plasma membrane, followed by neurotransmitter release (A) or insulin exocytosis (B).
